November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
But the vascular disrupting agent’s unexpected success in a cancer indication might not be as resounding as it seems.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Key catalysts approach for Orphazyme, Gemini and Immutep.